Investors give ImmunOs Therapeutics 11 million dollars

ImmunOs Therapeutics can finance its ongoing clinical trial up to the completion of Phase 1a with 11 million dollars in fresh capital. According to a press release, the Schlieren-based biotech company, which focuses on immuno-oncology, raised this sum in a series C financing round.

It was led by existing investors Gimv from Antwerp, Pfizer Ventures from New York, Mission BioCapital from San Francisco and BioMed Partners based in Basel. The new investor Double Point Ventures from Palm Beach in Florida and other existing venture capitalists participated. ImmunOs Therapeutics has "great potential as the first representative of a new generation of immunotherapies for the treatment of solid and liquid tumors," Campbell Murray, advisor at Double Point Ventures, is quoted as saying.

The proceeds will reportedly be used to continue financing the ongoing clinical trial of the drug IOS-1002 until the completion of clinical phase 1a. IOS-1002 is a novel, multifunctional immunotherapeutic for the treatment of advanced solid tumors that simultaneously targets multiple immune checkpoints and is based on a naturally occurring human leukocyte antigen (HLA).

"IOS-1002 is the world's most advanced HLA-based program addressing these relevant targets with such a novel multifunctional immunotherapy approach," said Reinhard Ambros, Executive Chairman of ImmunOs Therapeutics. As part of this round, Steve Tregay, the Managing General Partner of Mission BioCapital, has joined the Board of Directors.

ImmunOs Therapeutics AG is a spin-off of the University of Zurich and the University of Basel, based in the Bio-Technopark Schlieren-Zurich. ce/mm